GADAVIST
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
MRI/MRA contrast agent; gadobutrol for CNS, breast, vascular and cardiac diagnostic imaging.
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| No patent facts are recorded for this product. | ||||||||
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| No exclusivity facts are recorded in this product snapshot. | ||||||||
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| 215061 / 004 | APPLICATION_FINAL_OBSERVATION · FINAL_PRODUCT_DATE_UNVERIFIED | — | — | HENGRUI PHARMA | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 216081 / 006 | FINAL_APPROVAL · FINAL_APPROVED | 2022-11-17 | — | JIANGSU HENGRUI PHARMACEUTICALS CO LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 217480 / 002 | FINAL_APPROVAL · FINAL_APPROVED | 2023-03-15 | — | HAINAN POLY PHARMACEUTICAL CO LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 219146 / 004 | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-08 | — | ZENARA PHARMA PRIVATE LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 219287 / 003 | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-11 | — | VIWIT PHARMACEUTICAL CO LTD | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
| 215957 / 004 | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-29 | — | GE HEALTHCARE INC | N | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source |
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 5 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| 216081 / 006 | JIANGSU HENGRUI PHARMACEUTICALS CO LTD | FINAL_APPROVAL · FINAL_APPROVED | 2022-11-17 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 217480 / 002 | HAINAN POLY PHARMACEUTICAL CO LTD | FINAL_APPROVAL · FINAL_APPROVED | 2023-03-15 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 219146 / 004 | ZENARA PHARMA PRIVATE LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-08 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 219287 / 003 | VIWIT PHARMACEUTICAL CO LTD | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-11 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
| 215957 / 004 | GE HEALTHCARE INC | FINAL_APPROVAL · FINAL_APPROVED | 2026-06-29 | EXACT_PRODUCT · PENDING_PRODUCT_MAPPING | Source | — |
Decision evidence (1)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PRODUCT_STATUS | 2011-03-14 | EXCLUSION_BASIS | MRI/MRA contrast agent; gadobutrol for CNS, breast, vascular and cardiac diagnostic imaging. | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
No litigation or settlement record currently linked to this product.